{"id":"NCT00694122","sponsor":"Massachusetts General Hospital","briefTitle":"Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon","officialTitle":"Comparison of Lantus and NPH Insulin in the Dawn Phenomenon","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-06","primaryCompletion":"2010-11","completion":"2010-11","firstPosted":"2008-06-10","resultsPosted":"2014-10-21","lastUpdate":"2014-10-21"},"enrollment":27,"design":{"allocation":"NON_RANDOMIZED","model":"CROSSOVER","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 1 Diabetes","Dawn Phenomenon"],"interventions":[{"type":"DRUG","name":"Lantus (glargine)","otherNames":["Lantus (glargine): Sanolfi Aventis","NPH: Eli Lilly"]}],"arms":[{"label":"Glargine (Lantus) insulin","type":"ACTIVE_COMPARATOR"},{"label":"NPH insulin","type":"ACTIVE_COMPARATOR"}],"summary":"1. To investigate the effect of insulin glargine (Lantusâ„¢) vs NPH insulin regarding glycemic control during the early AM (dawn phenomenon) in individuals with type 1 diabetes.\n2. To measure hormones implicated in the pathogenesis of the dawn phenomenon in individuals with type 1 diabetes.","primaryOutcome":{"measure":"Blood Glucose Area Under the Curve (AUC)","timeFrame":"Overnight","effectByArm":[{"arm":"Glargine (Lantus) Insulin","deltaMin":1673.33,"sd":760.7},{"arm":"NPH Insulin","deltaMin":1395,"sd":384.9}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.05"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":10},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":15},"commonTop":[]}}